Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Oral Microbiome Composition Reflects Risk for Esophageal Cancers

By LabMedica International staff writers
Posted on 12 Dec 2017
Esophageal cancer is the eighth most common cancer and the sixth leading cause of cancer death worldwide. Because the disease is often not discovered until it has reached an advanced stage, five-year survival rates range from about 15% to 25% worldwide.

Bacteria may play a role in esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), although evidence is limited to cross-sectional studies. An analysis of bacteria present in the mouth showed that some types of bacteria that lead to periodontal disease were associated with higher risk of esophageal cancer.

Medical scientists at the NYU Langone School of Medicine (New York, NY, USA) and their colleagues collected oral wash samples from 122,000 participants in two large health studies. In 10 years of follow-up, 106 participants developed esophageal cancer. In a prospective case-control study, the investigators extracted DNA and sequenced oral wash samples, allowing the investigators to compare the oral microbiomes of the esophageal cancer cases and the cancer-free cases. Oral bacteria were assessed using 16S rRNA gene sequencing in pre-diagnostic mouthwash samples from n = 81/160 EAC and n = 25/50 ESCC cases/matched controls.

The team found that found the periodontal pathogen Tannerella forsythia was associated with a higher risk of EAC. Furthermore, they found that depletion of the commensal genus Neisseria and the species Streptococcus pneumoniae was associated with lower EAC risk. Bacterial biosynthesis of carotenoids was also associated with protection against EAC. Finally, the abundance of the periodontal pathogen Porphyromonas gingivalis trended with higher risk of ESCC. Overall, the findings have potential implications for the early detection and prevention of EAC and ESCC.

Jiyoung Ahn, PhD, an associate professor, and senior author of the study, said, “Esophageal cancer is a highly fatal cancer, and there is an urgent need for new avenues of prevention, risk stratification, and early detection. Our study indicates that learning more about the role of oral microbiota may potentially lead to strategies to prevent esophageal cancer, or at least to identify it at earlier stages. The next step is to verify whether these bacteria could be used as predictive biomarkers.” The study was published in the December 2017 issue of the journal Cancer Research.

Related Links:
NYU Langone School of Medicine


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Auto Clinical Chemistry Analyzer
cobas c 703
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.